Chronic lymphocytic leukemia has a survival time of twenty years, which depends on the patient’s stage. The prognosis of patients with different chronic lymphocytic leukemias is highly heterogeneous. Gender, age, physical status, concomitant diseases, peripheral blood lymphocyte count and doubling time, and clinical and laboratory markers such as LDH, β2-microglobulin (β2-MG), and thymidine kinase 1 (TK1) are important traditional prognostic factors. Two clinical staging systems, Rai and Binet, are most commonly used for clinical assessment of prognosis. Age greater than 65 years, Rai stage I-IV or Binet stage B-C are indicators of poor prognosis. It is also important to live a nutritious lifestyle with vitamins and protein-rich foods, which can be very beneficial in treating the disease and prolonging the patient’s lifespan. Chronic lymphocytic leukemia is recommended to seek timely medical attention and active treatment in order to prolong life.